PETRI DISH PERSPECTIVES

Manead Khin
  • 0.0(0개의 평가)
  • 생명 과학

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

  1. 1일 전

    Episode 69: Summit Therapeutics

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely watched oncology companies in the world. At the center of the story is ivonescimab, a next-generation bispecific antibody targeting both PD-1 and VEGF and a drug that could potentially challenge Merck’s blockbuster Keytruda. We’ll dive into Summit’s origins, the company’s dramatic pivot, the story behind its partnership with China’s Akeso, and the science behind why combining immune checkpoint inhibition with VEGF blockade could create a powerful new approach to cancer treatment. We’ll also break down the clinical data in lung cancer, Summit’s growing pipeline, the massive commercial opportunity, and the risks surrounding regulatory approval, clinical durability, and the company’s heavy dependence on a single lead asset. But Summit’s story goes far beyond one cancer drug. Ivonescimab represents a broader shift in how medicines are discovered and commercialized, with innovative assets increasingly emerging from Chinese biotech and being licensed by Western companies for global development. Could Summit become the company that brings a new generation of cancer therapeutics to the world and could ivonescimab really become a challenger to Keytruda? 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #SummitTherapeutics #Ivonescimab #Biotech #Biotechnology #Pharma #Oncology #Cancer #CancerResearch #Immunotherapy #BispecificAntibodies #PrecisionMedicine #DrugDevelopment #ClinicalTrials #Keytruda #Merck #ChineseBiotech #Healthcare #LifeSciences #PharmaceuticalIndustry Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  2. 8월 13일

    Episode 68: Guardant Health

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Guardant Health, one of the companies leading the shift toward blood-based cancer detection and precision oncology. Founded by genomic scientists Helmy Eltoukhy and AmirAli Talasaz, Guardant is betting that a simple blood draw can reveal critical information about the biology of a tumor, from identifying mutations and guiding treatment to monitoring residual disease and potentially detecting cancer earlier. We'll dive into the science behind liquid biopsy and circulating tumor DNA, Guardant's evolution from Guardant360 into a broader precision-oncology platform, the rise of its Shield colorectal cancer screening test, and the company's growing role in pharmaceutical drug development, real-world evidence, and AI. We'll also explore the promise and major challenges of multi-cancer early detection, including the questions around sensitivity, false positives, reimbursement, and whether detecting cancer earlier actually translates into better outcomes. Because the future of cancer care may not just be about developing better treatments, but about being able to continuously read what cancer is doing inside the body from something as simple as a blood sample. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #GuardantHealth #LiquidBiopsy #Cancer #Oncology #Biotech #Healthcare #PrecisionMedicine #CancerDetection #Genomics #ctDNA #Diagnostics #HealthTech #Pharma #AI #Biotechnology #FutureOfHealthcare Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  3. 8월 6일

    Episode 67: Epic Systems

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Epic Systems, the privately held healthcare technology company that has quietly built much of the digital infrastructure behind American healthcare. From Judy Faulkner founding Epic in a Wisconsin basement to becoming the dominant electronic health record platform, Epic has transformed how hospitals, physicians, and patients interact with medical information. We'll dive into Epic's founding story, the evolution of its electronic health record, the rise of MyChart and Cosmos, and how Epic built a massive competitive moat through interoperability, data, workflow integration, and switching costs. We'll also explore its growing role in artificial intelligence, how Epic is embedding AI directly into clinical workflows, and the battle with companies like Oracle Health to control the future of healthcare data. Because the next generation of healthcare won't just be about developing better drugs and devices, it will be about who controls the information infrastructure connecting patients, providers, data, and AI. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #EpicSystems #Healthcare #HealthTech #Biotech #Pharma #AI #ArtificialIntelligence #DigitalHealth #HealthcareInnovation #JudyFaulkner #EHR #HealthData #MedTech #FutureOfHealthcare Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  4. 8월 1일

    July 2026: Biotech & Pharma NEWS Roundup

    Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by AI cementing itself as a core part of drug discovery, with partnerships spanning Anthropic, NVIDIA, Insilico Medicine, and major pharmaceutical companies. At the same time, billion-dollar licensing deals and acquisitions showed that large pharma is aggressively buying innovation rather than building everything internally, particularly in obesity, oncology, radiopharmaceuticals, and gene editing. Regulatory headlines—from the FTC's lawsuit against Hims & Hers to renewed debates around animal testing—reminded us that policy is evolving just as quickly as the science. And with companies like Apnimed and Scribe Therapeutics successfully entering the public markets, investor confidence appears to be returning to biotech. The takeaway is clear: the future of healthcare will be shaped by the convergence of biology, artificial intelligence, precision medicine, and strategic dealmaking—and this month may be remembered as another major step toward that future. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  5. 7월 30일

    Episode 66: Scribe Therapeutics

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Scribe Therapeutics, one of genome editing's most ambitious companies aiming to move beyond first-generation CRISPR. Rather than accepting the size, delivery, and precision limitations of traditional Cas9, Scribe is redesigning the molecular machinery itself, building smaller, faster, and more versatile X-Editors and pioneering the future of epigenetic regulation. We'll dive into the origins of CRISPR from bacterial immune systems to Nobel-winning breakthroughs, the protein engineering philosophy of co-founder Jennifer Doudna and Benjamin Oakes, and why pharmaceutical giants like Biogen, Eli Lilly, and Sanofi have poured resources into its platform. We'll also break down its pipeline targeting cardiometabolic diseases, rare genetic disorders, and the promise of reversible gene silencing. Because the next era of genetic medicine won't just belong to those who discover biology, but to those who engineer it into safer, more precise cures. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ScribeTherapeutics #Biotech #CRISPR #GeneEditing #ProteinEngineering #Genomics #Genetics #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Cardiometabolic #Epigenetics #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  6. 7월 23일

    Episode 65: Apogee Therapeutics

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Apogee Therapeutics, one of biotech's newest immunology companies aiming to redefine autoimmune disease through next-generation antibody engineering. Rather than chasing entirely new biological targets, Apogee is focused on improving what already works, developing longer-lasting biologics that could reduce injections from every few weeks to every few months. We'll dive into the evolution of modern immunology, the science behind cytokines and Fc engineering, how Apogee emerged from biotech incubator Paragon Therapeutics, and why investors have poured hundreds of millions of dollars into its vision. We'll also break down its pipeline, including APG777, APG808, and other promising candidates targeting eczema, asthma, inflammatory bowel disease, and beyond. Because sometimes the biggest innovation isn't discovering new biology, it's engineering better medicines for the patients who depend on them. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ApogeeTherapeutics #Biotech #Immunology #AutoimmuneDisease #Biologics #AntibodyEngineering #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Dermatology #Asthma #Inflammation #ProteinEngineering #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  7. 7월 16일

    Episode 64: Conception Bio

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Conception Bio, one of the most ambitious biotechnology companies working at the intersection of stem cell biology, reproductive medicine, and regenerative science. Their mission? To make eggs from ordinary cells through in vitro gametogenesis (IVG), a breakthrough that could fundamentally change how we think about infertility, fertility preservation, and human reproduction. We'll dive into the science behind IVG, the pioneering research that made the field possible, the founders' vision, and why investors believe reproductive biology could become one of biotech's next major frontiers. We'll also discuss the enormous technical hurdles, ethical questions, and potential applications for cancer survivors, age-related infertility, LGBTQ+ family building, and beyond. Because the next revolution in medicine may not be about curing disease, it may be about creating life's very first cell. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ConceptionBio #Fertility #IVF #StemCells #RegenerativeMedicine #Biotech #ReproductiveBiology #InVitroGametogenesis #IVG #DrugDiscovery #Healthcare #LifeSciences #DevelopmentalBiology #PrecisionMedicine #WomenInScience #Biotechnology #SciencePodcast #FutureOfMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  8. 7월 9일

    Episode 63: Enveda Biosciences

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Enveda Biosciences, one of the most exciting AI-native biotech companies redefining how drugs are discovered. While most pharmaceutical companies build vast synthetic chemical libraries, Enveda is using artificial intelligence, metabolomics, and mass spectrometry to unlock the world's largest and largely untapped chemical library: nature. We'll trace the history of natural product drug discovery, from penicillin and paclitaxel to the AI revolution, dive into founder Viswa Colluru's vision of creating a searchable map of nature's chemistry, and explore how Enveda's platform is transforming plants, fungi, and microbes into tomorrow's medicines. We'll also discuss the company's growing clinical pipeline, why investors have poured hundreds of millions into the platform, and whether AI can finally solve one of drug discovery's oldest challenges. Because sometimes, the future of medicine isn't invented, it evolves. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Enveda #ArtificialIntelligence #AI #DrugDiscovery #Biotech #NaturalProducts #MachineLearning #Metabolomics #Pharmaceuticals #Healthcare #PrecisionMedicine #MedicinalChemistry #LifeSciences #Biotechnology #Innovation #ClinicalResearch #DrugDevelopment #SciencePodcast #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

모두 보기(78개)

소개

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

정보

  • 제작진
    Manead Khin
  • 방송 연도
    2025년 - 2026년
  • 에피소드
    78
  • 등급
    전체 연령 사용가
  • 저작권
    © 2026 PETRI DISH PERSPECTIVES
  • 웹사이트 보기
    PETRI DISH PERSPECTIVES

좋아할 만한 다른 항목